ArticleJournal of cannabis research2026
A novel enema formulation containing cannabidiol and sodium propionate for ulcerative colitis: preclinical assessment in a murine model.
Article in Journal of cannabis research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis (UC) is a chronic inflammatory bowel disease characterized by mucosal inflammation, epithelial barrier disruption, and immune dysregulation. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, and sodium propionate (Na-P), a short-chain fatty acid, posses complementary anti-inflammatory and epithelial-protective properties. This study aimed to evaluate the safety and efficacy of a novel rectal enema formulation combining CBD and Na-P in a murine model of dextran sodium sulfate (DSS)-induced colitis.
methodsExperimental colitis was induced in C57BL/6 mice via 2.5% DSS administration for five days. Mice received one of 4 daily rectal treatments from day 4 to day 11: saline, hyaluronic acid (HA, vehicle), HA + CBD, HA + Na-P, or HA + CBD+Na-P. Clinical disease activity was monitored through the Disease Activity Index (DAI), body weight, colon length, and histopathological evaluation.
resultsColon length analysis demonstrated a 34.7% increase in length in the combination group versus saline control, significantly exceeding improvements observed with CBD or Na-P alone (p < 0.001). The combination treatment of CBD and Na-P led to a significant and sustained reduction in DAI scores compared to controls and monotherapies. Notably, the combination group exhibited a steeper improvement in DAI from day 6 onwards and showed superior outcomes on day 11 (p < 0.004 vs. HA). Body weight loss was markedly attenuated in the combination group, with statistical significance observed from day 6 (p < 0.05), while single-agent treatments exhibited only partial benefit. Histopathological scores were reduced in the combination group, accompanied by decreased neutrophilic infiltration and attenuation of mucosal damage, though statistical significance was not reached compared to monotherapies. Importantly, no hemorrhages or fibrin deposits were observed in any group, supporting the safety profile of the combination treatment.
conclusionsThis preclinical study demonstrates that rectal administration of a CBD and Na-P enema exerts potential synergistic therapeutic effects in experimental UC, effectively reducing disease severity, preserving colon morphology, and mitigating histopathological damage. These findings support further clinical investigation of this novel dual-targeted approach for UC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.